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Abstract
Background: Lymphatic filariasis and onchocerciasis are debilitating diseases caused by filarial nematodes. Disease
pathogenesis is induced by inflammatory responses following the death of the parasite. Wolbachia endosymbionts
of filariae are potent inducers of innate and adaptive inflammation and bacterial lipoproteins have been identified
as the ligands that bind toll-like receptors (TLR) 2 and TLR6. Lipoproteins are important structural and functional
components of bacteria and therefore enzymes involved in Wolbachia lipoprotein biosynthesis are potential
chemotherapeutic targets.
Results: Globomycin, a signal peptidase II (LspA) inhibitor, has activity against Gram-negative bacteria and a
putative lspA gene has been identified from the Wolbachia genome of Brugia malayi (wBm). The amino acids
required for function are strictly conserved and functionality was verified by complementation tests in a
temperature-sensitive Escherichia coli lspA mutant. Also, transformation of wild type E. coli with Wolbachia lspA
conferred significant globomycin resistance. A cell-based screen has been developed utilizing a Wolbachia-
containing Aedes albopictus cell line to assay novel compounds active against Wolbachia. Globomycin was
screened using this assay, which resulted in a dose-dependent reduction in Wolbachia load. Furthermore,
globomycin was also effective in reducing the motility and viability of adult B. malayi in vitro.
Conclusions: These studies validate lipoprotein biosynthesis as a target in an organism for which no genetic tools
are available. Further studies to evaluate drugs targeting this pathway are underway as part of the A-WOL drug
discovery and development program.
Background
Lymphatic filariasis and onchocerciasis are leading causes
of global morbidity, with 150 million people afflicted and
1.5 billion people at risk. The filarial nematodes responsi-
ble for these diseases; Wuchereria bancrofti, Brugia
malayi (lymphatic filariasis) and Onchocerca volvulus
(onchocerciasis), have a mutualistic association with a
bacterial endosymbiont, Wolbachia pipientis.T h es y m -
biotic relationship is essential for parasite growth, devel-
opment, fecundity and survival [1].
Wolbachia have emerged as a novel target for antibiotic
therapy to treat filariasis. Antibiotic studies using ex vivo
and in vivo animal model systems (reviewed by [1]) and
extensive field trials have demonstrated the effectiveness
of antibiotics such as doxycycline in the treatment of
filariasis [2-14]. Depletion of Wolbachia leads to long-
term sterility and ultimately to the death of adult worms.
Furthermore, Wolbachia-targeted treatment has also
been shown to lead to a reduction in the severity and
improvement of lymphoedema and hydrocoele pathology
in lymphatic filariasis [3,5]. Despite these clear benefits of
doxycycline therapy over conventional treatments, the
extended period of treatment and contraindication in
children under eight and pregnancy compromises their
delivery through mass drug treatment programmes. This
has driven the formation of the A-WOL (anti-
Wolbachia)c o n s o r t i u mt od i s c o v e ra n dd e v e l o pn e w
drugs active against Wolbachia for the treatment of
filariasis that would be compatible with current control
programme strategies.
Wolbachia lipoproteins have emerged as potent stimula-
tors of the inflammatory pathogenesis of filarial disease
[15]. Genomic analysis indicates that Wolbachia contain
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N-acyltransferase, which is required for the triacylation of
apolipoproteins. This suggests that Wolbachia lipoproteins
cannot be triacylated and accounts for the recognition by
the diacyl-lipoprotein receptor complex TLR2/6 [15].
Bioinformatic and database searches consistently predicted
the presence of only three lipoproteins in Wolbachia:P e p -
tidoglycan-associated lipoprotein (PAL), a Type IV Secre-
tion System protein (VirB6) and Small protein A [15].
Lipoproteins are important structural and functional
components of bacteria and their biosynthesis is essen-
tial for bacterial viability. Globomycin, an inhibitor of
lipoprotein signal peptidase, LspA [16], has previously
been demonstrated to have potent anti-bacterial activity
against Gram-negative bacteria [17-20]. We therefore
sought to test whether globomycin was active against
Wolbachia and to validate lipoprotein biosynthesis as a
Wolbachia drug target.
Results
Identification and verification of a functional wBm lspA
gene
Putative lspA genes were identified from the available
genome databases of wBm and Wolbachia endosym-
bionts of Drosophila species. The deduced amino acid
sequence of the putative Wolbachia (including wBm)
LspA proteins contain a predicted signal peptide with
three transmembrane domains, which are evolutionarily
conserved features in LspA proteins (Figure 1). High
sequence identity (80-81%)/similarity (88%) was
observed between B. malayi Wolbachia LspA and Dro-
sophila Wolbachia LspA homologs, all containing the
five conserved catalytic residues [21], although a low
amino acid identity (25%)/similarity (49%) was revealed
when compared to the Escherichia coli LspA homolog
(Figure 1). The conservation of the amino acids required
for function suggests that the wBm LspA gene should
be functional.
wBm LspA recombinant clone is active in a
complementation test
To confirm activity of LspA, the recombinant clone was
tested using a complementation assay in an E. coli strain
with a ts LspA mutant. The point mutation in the lspA
gene of E. coli Y815 strain confers temperature sensitiv-
ity to cell growth. At the non-permissive temperature
(42°C), cell growth is hindered by the accumulation of
prolipoproteins due to inactivation of LspA enzyme
[22]. The plasmids pET21-EcLspA.His (PC, positive con-
trol), pET21a-wBmLspA.His (T1: test 1), pGEX5.1-GST.
wBmLspA.His (T2, test 2), pET21a (NC1, negative con-
trol 1) and pGEX5.1 (NC2, negative control 2) were
transformed into E. coli strain Y815 for functional
complementation tests of growth. NC1, NC2 and T2
transformants did not grow at 42°C, while both PC and
T1 grew and formed visual colonies at the non-permis-
sive temperature, confirming the wBm lspA gene (T1) is
a functional LspA enzyme (Table 1).
Globomycin resistance assays confirm wBmLspA activity
Globomycin resistance assays in E. coli were conducted to
further test the function of the wBm lspA gene. LspA inhi-
bition by globomycin leads to the accumulation of unpro-
cessed prolipoproteins in the inner cell membrane and
thus hinders cell growth [16,23,24], while the inhibition
can be overcome by over-expression of a functional lspA
gene from other bacterial sources, which confers globomy-
cin resistance [21,25-27]. To confirm this with the wBm
lspA gene constructs, the plasmids NC1, PC, T1, NC2 and
T2 in T7 Express E. coli were tested in globomycin resis-
tance assays. With one exception, in the group without
IPTG induction, all transformants grew well in the
absence of globomycin and showed arrested growth when
treated with 100 μg/ml globomycin. The exception was
the PC transformant (E. coli transformed with pET21a-
EcLspA.His), which conferred globomycin resistance in
the absence of induction by IPTG (Figure 2). The signifi-
cant “leaky” expression of EcLspA.His was also detected
by western blot analysis (Figure 3). In the IPTG induction
set, the cell growth in both PC and T2 transformants
(E. coli transformed with pGEX5.1-GST.wBmLspA.His)
was dramatically inhibited even without addition of globo-
mycin, suggesting that a relatively high level of overexpres-
sion of EcLspA.His and GST.wBmLspA.His proteins alone
could hinder normal cell growth. wBmLspA.His (T1) was
expressed when induced with IPTG, but did not lead to
the significant growth inhibition observed for PC and T2
transformants. In the IPTG induction group, when treated
with 100 μg/ml globomycin, E. coli cells with over-
expressed EcLspA.His (PC), wBmLspA.His (T1) or GST.
wBmLspA.His (T2) conferred strong globomycin
resistance compared to negative controls (NC1 and NC2)
(Figure 3). A synthetic wBm lspA gene was created for
improving gene expression level in both E. coli Y815 and
T7 Express E. coli. However, no detectable improvement
was observed in both E. coli cell strains (data not shown).
Globomycin affects Wolbachia growth in a cell-based
assay
We investigated whether globomycin affected Wolbachia
growth in a cell-based assay using Wolbachia-infected
insect cells (C6/36Wp; [28]). Cultures were treated with
globomycin in a 96-well plate format and Wolbachia
growth was determined by qPCR targeting the Wolbachia
16S rRNA gene. As shown in Figure 4A, Wolbachia 16S
copy numbers were significantly reduced when compared
to the DMSO (1%) control (P < 0.01). This reduction was
dose-dependent and equated to log reductions of 1.33,
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respectively at day 10 after initiation of treatment, which
increased to between 1.88 and 2.48 by day 16. The reduc-
tion in 16S gene copy numbers achieved with globomycin
at 20 μg/ml, although significant (P <0 . 0 5 ) ,d i dn o t
extend beyond a 0.55 log-drop throughout the test per-
iod. A. albopictus 1 8 Sr R N Ag e n ec o p yn u m b e r sw e r e
also analyzed by qPCR in order to check for any effect of
globomycin on cell growth (Figure 4B) and to normalize
the 16S data by producing ratios of 16S to 18S gene copy
numbers (Figure 4C). Globomycin had no significant
effect on cell growth at concentrations up to and includ-
ing 80 μg/ml (Figure 4B), although 100 μg/ml globomycin
did have a small but significant effect on cell growth
(P < 0.05). The normalization of 16S copy numbers to
18S copy numbers did not affect the overall results
(Figure 4C).
Globomycin affects lipoprotein processing
As globomycin targets the enzyme signal peptidase II in
the lipoprotein biosynthesis pathway [16], any inhibition
that occurs should prevent the cleavage of the signal pep-
tide and thus result in an accumulation of the prolipo-
protein. Cells treated with globomycin were used to
assess the effect of this drug on lipoprotein processing in
Wolbachia. A western blot using antibody raised against
recombinant wBm PAL was conducted on lysates of cells
treated with globomycin or vehicle-control for 24 hours.
A ss h o w ni nF i g u r e5 ,g l o b o m y c i nt r e a t m e n ti n h i b i t e d
processing of the precursor of the Wolbachia lipoprotein
PAL in a dose-dependent manner. When compared to
Figure 1 Sequence alignment of LspA proteins. Sequence alignment of LspA proteins from Wolbachia of Brugia malayi (wBm, AAW71005),
Wolbachia of Drosophila melanogaster (wMel, AAS14450), Wolbachia of Drosophila willistoni (wWill, ZP_01314990), Ehrlichia canis (Eh. c,
AAZ68883), Anaplasma marginale (A.m, AAV86940), and Escherichia coli (E.coli, NP_414568). Genbank accession numbers follow the abbreviations
of each species indicated above. The conserved catalytic residues are indicated in bold font. The predicted signal peptides are labelled in pale
colour and the predicted transmembrane domains are marked by black bars above the alignment. Asterisks (*) denote identical residues, double
dots (:) denote conserved substitutions based on amino acid biochemical similarity and single dots (.) denote semi-conserved substitution. The
similarity rate is derived from the overall amino acid biochemical similarity of the compared proteins.
Table 1 Complementation assays in E. coli ts LspA
mutant Y815
E. coli Y815 LspA ts transformants 30°C 42°C
w/pET21a only (NC1) + -
w/pET21a-EcLspA.His (PC) + +
w/pET21a-wBmLspA.His (T1) + +
w/pGEX5.1 only (NC2) + -
w/pGEX5.1-GST.wBmLspA.His (T2) + -
Actively growing transformants were plated onto LB agar (100 μg/ml
ampicillin, 10 μg/ml tetracycline and 0.6 mM IPTG) and incubated at both the
permissive (30°C) and the nonpermissive (42°C) temperature for 3 days for
colony formation as described [21]. ‘+’ means growth, ‘-’ means no growth.
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15 kDa representing the mature lipoprotein, the globo-
mycin treated cells also showed an additional larger band
of approximately 18 kDa. This suggests that the target of
globomycin in Wolbachia is LspA and indicates that the
resulting inhibition of growth and death of bacteria is
due to the accumulation of prolipoprotein in the cyto-
plasmic membrane [16,23,24].
The effect of globomycin on the motility and viability of
B. malayi in vitro
The effect of this compound on nematode motility was
examined by incubating B. malayi adult females with
globomycin in vitro. Motility was assessed daily using a
method described by Rao and Weil [29]. Over the test
period of 10 days, globomycin reduced motility in a
dose-dependent manner (Figure 6A). The highest con-
centration of globomycin (100 μg/ml) rendered the
majority of worms inactive by day 3. Globomycin used
at a concentration of 50 μg/ml was also found to ren-
der the majority of the nematodes immotile by day 7
(Figure 6A). A similar dose dependent reduction in
motility was observed in male worms (data not shown).
At the end of the motility test period, worms were
collected for use in an MTT assay to assess viability.
Figure 6B shows reduced viability of those exposed to
the higher concentrations of globomycin, which at a
concentration of 100 μg/ml globomycin was significantly
reduced compared to vehicle-treated controls at 10 days
post-treatment (P < 0.05). Furthermore, the MTT result
for this treated group was not significantly different
from that obtained from dead worm controls (P =0 . 2 9 )
suggesting that globomycin at this concentration is able
to kill adult B. malayi in vitro.
Discussion
One of the objectives of the A-WOL consortium is to
identify and validate novel drug targets of Wolbachia to
Figure 2 Globomycin resistance assays of wBmlspA-transformed T7 express E. coli cells. Cell growth was measured at 600 nm (OD600).
NC1: pET21a vector only; PC: pET21a-EcLspA.His; T1: pET21a-wBmLspA.His; NC2: pGEX5.1 vector only; T2: pGEX5.1-GST.wBmLspA.His. Starting OD
is 0.1. Cells grow at 16°C for 16 hours.
Figure 3 Expression of recombinant LspA proteins in T7 express E. coli with and without IPTG induction. wBmLspA and EcLspA
transformed E. coli cell lysates (~ 200 μg total protein/well) were loaded. The expressed recombinant LspA proteins were detected with Mouse
anti-His monoclonal antibody (details in methods and materials). For each construct of samples without (w/o) and with (w/) IPTG induction are
shown, Lane 1 & 2: E. coli cell/pET21a (NC1), Lane 3 & 4: E. coli cell/pET21a-EcLspA.His (PC), Lane 5 & 6: E. coli cell/pET21a-wBmLspA.His (T1), Lane
7&8 :E. coli cell/pGEX5.1 (NC2), Lane 9 & 10: E. coli cell/pGEX5.1-GST.wBmLspA.His (T2). The predicted molecular weights of recombinant
wBmLspA.His, EcLspA.His and GST.wBmLspA.His proteins are 19, 20 and 44 kDa, respectively.
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assays. Validating a potential drug target in Wolbachia,
however, is problematic as these bacteria are not amen-
able to genetic manipulation. We have therefore used
complementation assays of mutant E. coli to validate
enzymatic function and a pharmacological inhibitor of
lipoprotein biosynthesis, globomycin, to determine
the effect of inhibition of lipoprotein biosynthesis on
Wolbachia in a whole organism cell-based drug screen-
ing assay.
wBm contains two genes encoding enzymes of the lipo-
protein biosynthesis pathway [15,30]: lgt,p r o l i p o p r o t e i n
diacylglyceryl transferase and lspA, lipoprotein signal
peptidase. The third enzyme in the pathway responsible
for triacylation, typically found in other bacteria, appears
to be absent from Wolbachia. Although Wolbachia is
intractable to genetic manipulation we were able to con-
firm that Wolbachia LspA is functional in E. coli, despite
having only 25% identity and 49% amino acid similarity
to its E. coli homolog. wBm LspA has retained the con-
served catalytic residues required for function and can
genetically complement deficient growth of an lspA ts
E. coli mutant. Globomycin is a known inhibitor of LspA
and overexpression of Wolbachia LspA in wild-type
E. coli conferred resistance to this compound allowing us
to conclude that the expressed gene was functional.
We used a ts E. coli LspA mutant to confirm the func-
tionality of the wBmLspA gene (Table 1). As expected,
the N-terminal GST-fused full-length wBmLspA.His
(T2) cannot rescue the ts mutant (Table 1); likely due to
the loss of signal peptide at its N-terminus, indicating
that proper subcellular localization of LspA is crucial for
its functional activity. However, the misplaced GST.
wBmLspA.His still conferred strong globomycin resis-
tance, although its overexpression appeared to be toxic
to the E. coli cell even without addition of globomycin
(Figure 2). This may imply that the mis-localized GST.
Figure 4 Dynamics of Wolbachia and cell response to globomycin over 16 days. Wolbachia growth was measured by qPCR targeting the
16S rRNA gene (A), C6/36Wp cell growth was measured by targeting the 18S rRNA gene (B) and data was normalized by calculating the ratio of
16S copies to 18S copies (C). Error bars represent standard deviations from triplicate cultures.
Figure 5 Inhibitory effect of globomycin on Wolbachia PAL
processing. C6/36Wp cells were incubated with three
concentrations of globomycin or DMSO control for 24 hours and
extracts were subjected to Western blotting using antibodies to
Wolbachia PAL. Cells treated with globomycin have 2 PAL proteins
detectable, indicating inhibition of full lipoprotein processing.
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for globomycin binding. However, after removal of the
signal peptide, GST-fused mature wBmLspA.His totally
lost resistance to globomycin (data not shown).
The leaky expression of EcLspA.His (PC) conferred
strong resistance to globomycin without significantly
reducing E. coli cell growth, while its excessive overex-
pression, induced by IPTG, although still conferring glo-
bomycin resistance, led to striking cell growth inhibition
(Figure 2). This might suggest that the expression of
LspA is required and at the same time strictly regulated
for achieving normal cell growth, which is in line with
t h ef a c tt h a tc o d o n - o p t i m i z e dwBm LspA gene did not
improve its expression in E. coli.
Lipoproteins perform multiple essential structural and
functional roles in bacteria. For example, the lipoprotein
PAL is not only involved in the maintenance of outer
membrane integrity [31] but has also been demonstrated
to be involved in the uptake of nutrients across the
membrane of Pseudomonas putida [32] and required for
virulence in Haemophilus ducreyi infection of humans
[33]. Therefore the inhibition of lipoprotein biosynthesis
is likely to affect multiple functions in bacteria. Globo-
mycin is a 19-membered depsipeptide antibiotic isolated
from actinomycetes strains [18-20], which targets LspA.
Although not commercially available for use as an anti-
biotic, it has been widely used as a research tool to
determine the requirement of lipoprotein biosynthesis
for a range of biological features of bacteria [34,35]. In
addition to using globomycin to assess the functionality
of the Wolbachia LspA enzyme in transformed E. coli,
we used this compound to assess the importance of the
lipoprotein biosynthesis pathway in a Wolbachia cell
line (C6/36Wp) and in B. malayi adult nematodes
cultured in vitro.
The C6/36Wp system is currently the primary screen
used in the A-WOL drug discovery program for Wolba-
chia http://www.a-wol.com, and aims to discover novel
compounds with anti-Wolbachia activity. In this study,
globomycin was shown to have a dose-dependent anti-
Wolbachia effect on the C6/36Wp cell line, demonstrat-
ing a new class of antibiotic active against Wolbachia.
Globomycin acts by an inhibition of a prolipoprotein
processing enzyme, resulting in an accumulation of the
prolipoprotein in the cell envelope [16,23,24] and this
inhibition occurs through the non-competitive binding
of globomycin to the lipoprotein signal peptidase and
not by binding to the substrate [16]. Treatment of
Wolbachia cell cultures with globomycin resulted in the
accumulation of prolipoprotein suggesting a similar
mode of action occurs in Wolbachia. Furthermore, glo-
bomycin affected both the processing of OmpA in Ehrli-
chia chaffeensis, an obligate intracellular bacterium
closely related to Wolbachia pipientis, and its ability to
infect HL-60 cells [35].
Globomycin was also shown to have adverse effects on
the motility and viability of adult female and male B.
malayi nematodes in vitro. QPCR analysis did not, how-
ever, demonstrate any differences in Wolbachia load
between treated groups (data not shown) suggesting
that the Wolbachia qPCR assay may not have sufficient
sensitivity to detect effects on Wolbachia load over this
time frame in nematodes, perhaps due to the slower
growth rate of nematode Wolbachia compared to insect
Wolbachia in cell culture. Notably doxycycline also fails
to produce a reduction in Wolbachia load over this time
frame. An alternative explanation is that inhibition of
Wolbachia lipoprotein biosynthesis is sufficient to affect
nematode motility and viability independent of or prior
to any effect on Wolbachia load. We also cannot rule
out a direct effect of globomycin on nematode motility
and viability and alternative mechanisms of action have
been suggested in Mycobacterium tuberculosis [36],
Figure 6 The effect of globomycin on B. malayi motility and
viability. The motility of worms cultured in the presence of
globomycin was scored daily and is presented as percentages of
the control (1% DMSO) motility (A). At the end of the test period
worms were used in an MTT assay to assess effects on nematode
viability (B). Remaining worms were used for qPCR analysis of
Wolbachia numbers per worm (data not shown).
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bacterium independently of its effect on LspA.
Conclusions
In summary, in the search for new anti-wolbachial
drugs, we have identified and validated the lipoprotein
biosynthesis pathway as a target for Wolbachia drug dis-
covery and development and shown that globomycin, a
drug targeting lipoprotein signal peptidase, is active
against Wolbachia.
Methods
Globomycin
Globomycin was obtained as a kind gift from Professor
Masatoshi Inukai of International University of Health
and Welfare, Tochigi, Japan. A stock solution of 10 mg/
ml was made in dimethylsulphoxide (DMSO) and stored
in single-use aliquots at -80°C. Before use, the stock
solution was diluted in the appropriate culture medium
to the appropriate concentrations.
LspA gene cloning
B. malayi DNA (including Wolbachia DNA) was
extracted with DNeasy extraction kit (Qiagen) from live
adult worms purchased from TRS Labs, Athens, GA.
Primers were designed with restriction endonuclease
sites (Additional File 1; Table S1), based on the available
wBm and E. coli lspA gene sequences (Genbank acces-
sion numbers AE017321 and NC_000913, respectively).
The full-length lspA genes from B. malayi Wolbachia
(wBm) and E. coli were amplified by PCR using Phusion
polymerase (New England Biolabs, NEB), and were
cloned into the expression vector pET21a+ with a
C-terminal 6XHis tag (Novagen) after digestion with
corresponding restriction endonucleases (NEB). The
generated plasmids were named as pET21a-wBmLspA.
His and pET21a-EcLspA.His, respectively. wBmlspA
gene with an added C-terminal 6XHis tag was also
cloned into the expression vector pGEX5.1 (GE Health-
care) with a N-terminal GST fusion, named as
pGEX5.1-GST.wBmLspA.His. A codon-optimized ver-
sion of wBmlspA was designed by DNAworks oligonu-
cleotide designing software [37], synthesized using USER
cloning methods [38] and cloned into pET21a+ vector
for improvement of gene expression. The T7 Express
competent E. coli strain 2566 (NEB) was used as a host
for plasmid recipients. The sequences of the lspA gene
inserts were verified by DNA sequencing.
Recombinant LspA protein expression in E. coli
Expression of C-terminally 6XHis tagged wBmLspA, EcL-
spA, and GST.wBmLspA recombinant proteins in T7
Express E. coli strain with and without isopropyl-beta-D-
thiogalactopyranoside (IPTG) inductions was detected by
Mouse anti-His tag monoclonal antibody and subsequent
secondary horseradish peroxidase (HRP) conjugated Rab-
bit anti-Mouse IgG antibody (Novagen) in combination
with the use of LumiGLO
(r) chemiluminescent reagent
and peroxide (Cell Signaling Technology, CST).
ts E. coli lspA mutant
E. coli strain Y815 is a type II lipoprotein signal pepti-
dase [21] temperature sensitive (ts) mutant, containing a
pHY001 vector, which carries a tetracycline resistance
gene (tet
R) and a lpp gene encoding a major outer mem-
brane lipoprotein inducible by IPTG [22].
Complementation assays in E. coli
The constructs pET21a-wBmLspA.His, pET21a-EcLspA.
His, and pGEX5.1-GST.wBmLspA.His, along with the
vector only controls, pET21a and pGEX5.1, were trans-
formed into E. coli Y815 cells with appropriate antibiotic
selection. The E. coli Y815 ts lspA mutant grows nor-
mally at 30°C, but not at 42°C for colony formation.
The detailed protocol is described in [21].
Sequence analysis of Wolbachia lspA genes
The LspA protein sequences from different Wolbachia
strains and other reference species (shown in Figure 1)
were retrieved from NCBI Genbank database [39] via
protein-protein BLAST similarity searches and were
aligned using CLUSTALX 1.83 [40]. The sequences in
the alignment were further analyzed by Genedoc 2.6
[41] for calculating percentage of amino acid identity/
similarity, TMHMM 2.0 [42] for prediction of trans-
membrane domains, and SignalP 3.0 [43] for predicting
signal peptide.
Globomycin resistance assays in E. coli
The experiments were devised and developed from a
previous strategy [21]. T7 Express E. coli were trans-
formed with plasmids pET21a-wBmLspA.His, pET21a-
EcLspA.His, and pGEX5.1-GST.wBmLspA.His, along
with the vector only controls pET21a and pGEX5.1.
Transformants were grown to 0.6 ~ 1.0 OD600 at 37°C
in Luria-Bertani (LB) medium containing 100 μg/ml
ampicillin before being diluted to 0.1 OD600. The diluted
samples were equally divided into IPTG (0.1 mM)
induced and non-induced groups. In each group, the
samples were further divided into globomycin treatment
(100 μg/ml) and non-treatment subgroups. All samples
were grown at 16°C for 16 hours with shaking. The
samples with high cell density were diluted before mea-
surement by spectrophotometer at 600 nm for accuracy.
The samples had two replicates in each experiment and
three independent experiments were carried out in total.
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An Aedes albopictus cell line C6/36 (ATCC number
CRL-1660) stably infected with Wolbachia pipientis
wAlbB (C6/36Wp) was routinely cultured in Leibovitz-
15 medium containing 2 mM L-glutamine, 5% foetal
bovine serum, 1% non-essential amino acids and 2%
tryptose phosphate broth at 26°C [28]. For drug assays,
C6/36Wp cells were cultured in 96-well microtitre
plates at a concentration of 10,000 cells per well over-
night. Globomycin and vehicle (DMSO) controls were
added in triplicate at the appropriate concentration,
based on previous publications [17,19,21], the following
day and replaced every 4 days. Samples were collected
at appropriate timepoints by washing once in phosphate
buffered saline (PBS) then adding 150 μlW i z a r d ®S V
Lysis Buffer (Promega) to each well. Lysates were stored
at -80°C for processing at a later date.
Quantitative PCR (qPCR)
Genomic DNA was prepared from cell lysates using the
Wizard
(r) SV 96 Genomic DNA Purification System (Pro-
mega) according to the manufacturer’si n s t r u c t i o n sa n d
eluted in 100 μl water. qPCR targeting the 16S rRNA gene
of Wolbachia and the 18S rRNA gene of the cell was con-
ducted according to that described by [44] with minor
modifications. Briefly, reaction mixtures consisted of a pair
of primers (5’-TTGCTATTAGATGAGCCTATATTAG-3’
and 5’-GTGTGGCTGATCATCCTCT-3’ for 16S
ribosomal DNA qPCR and 5’-CCGTGATGCCCTTA-
GATGTT-3’ and 5’-ATGCGCATTTAAGCGATTTC-3’
for 18S ribosomal qPCR) at 200 nM each, 1 × SYBR Green
reaction mix (Qiagen) and 2 μl DNA in the case of 16S
qPCR or 1 μl DNA for 18S qPCR. Quantitative DNA stan-
dards were prepared as serial dilutions from stock single-
stranded oligonucleotides representing the full-length
amplicons (Sigma Genosys) and used at 5 × 10
6 to 5 × 10
0
copies [44], in duplicate reactions. Assays were performed
on a DNA Engine PTC-200 thermocycler (MJ Research,
GRI) with Chromo4 real-time PCR detection system (Bio-
Rad) using the following conditions: denaturation at 95°C
for 15 min followed by 40 cycles of 95°C for 15 sec, 55°C
for 30 sec and 72°C for 15 sec. Melting curve analysis was
performed between 50°C and 95°C to confirm specificity.
Copy number was calculated from the standard curve by
standard methods.
Western blot analysis
C6/36Wp cells were cultured in duplicate as described
for the cell-based drug assays. Following 24 hours of glo-
bomycin treatment, cells were washed once in PBS then
lysed by adding 25 μl of ice-cold RIPA buffer (Pierce)
containing freshly added protease inhibitor solution (GE
Healthcare) and incubating at room temperature for
5 min. Duplicate cultures were pooled and centrifuged at
16,000 × g for 15 min and the lysates were collected. Cell
lysates were diluted in 2 × Laemmli sample buffer con-
taining reducing agents (Sigma Aldrich) and incubated at
96°C for 10 min. 25 μl of samples were subjected to SDS-
PAGE using 15% Tris-HCl gels (Bio-Rad) and protein
bands were transferred onto a 0.45 μm PVDF membrane.
After blocking for 2 h in 4% milk diluted in Tris-buffered
saline (TBS) containing 0.1% Tween, membranes were
incubated overnight at 4°C in affinity-purified anti-
B. malayi Wolbachia PAL (wBmPAL) antibody [15]
diluted 1 in 5,000 in blocking buffer. Membranes were
washed at least four times in TBS 0.1% Tween then incu-
bated with secondary antibody (goat-anti-rabbit-HRP,
Perkin Elmer) diluted 1 in 5,000 for one hour at room
temperature. Following washing, the blots were devel-
oped using the Supersignal West system (Pierce).
In vitro B. malayi assays
Adult B. malayi were obtained from TRS Laboratories,
Athens, Georgia. Female and male adult worms were cul-
tured in 12-well plates, five worms per well, three wells
per group in 2.5 ml RPMI containing 10% foetal bovine
serum and penicillin-streptomycin (Invitrogen, 200 U/
ml/200 μg/ml final concentration). Globomycin and vehi-
cle controls were added the following day and motility
was scored daily in a blinded manner using the scoring
system described by [29]. The assay was terminated at
day 10 and worms were used in an MTT assay to assess
viability [45]. Worms were added singly to wells of a 96
well plate and washed with 200 μlP B S .2 0 0μlM T Tw a s
added at a final concentration of 0.5 mg/ml in PBS and
the plate was incubated for two hours at 37°C with 5%
CO2. MTT solution was removed and worms were
washed twice with PBS then incubated in 200 μlo f
DMSO for one hour at 37°C, 5% CO2 in order to solubi-
lise the formazan product. The plate was read at 490 nm
using DMSO alone as a blank. Frozen B. malayi were
used as non-viable controls. Remaining worms were
stored at -80°C for DNA extraction at a later date.
Statistical analysis
Differences between groups were assessed using Stu-
dent’s T test.
Additional material
Additional file 1: Table S1 - Wolbachia (wBm) and E. coli LspA gene
specific primers used. Wolbachia (wBm) and E. coli LspA gene specific
primers were used for PCR amplification of the full-length coding
sequences for cloning into pET21a+ vector and pGEX5.1 vector. Primers
were designed based on sequence information available in Genbank http://
www.ncbi.nlm.nih.gov. Restriction enzyme sites in primers are underlined.
Abbreviations used: wBm: Wolbachia endosymbiont of Brugia malayi,E c :E.
coli, f: forward primer, r: reverse primer, LspA: type II lipoprotein signal
peptidase.
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